What Novo Nordisk Didn’t Say: The Growing Danger Behind Ozempic

Publish Date : 06/20/2025

While Novo Nordisk flooded the public with glowing ads – medical researchers, health agencies, and even their own clinical data revealed a very different story: severe gastrointestinal issues linked to semaglutide drugs like Ozempic, Wegovy, and Rybelsus. Symptoms included gastroparesis (stomach paralysis), intestinal obstruction, and ileus — a dangerous condition potentially leading to hospitalization or emergency surgery.

The science wasn’t hidden. As far back as 2010, researchers warned that GLP-1 drugs like semaglutide slowed digestion and could cause complications. By 2023, those warnings turned into headlines. Patients shared harrowing stories of vomiting, constant nausea, and lost time from work. Some couldn’t eat or function. Case studies detailed severe GI events and surgeries linked to the drug — but Novo Nordisk never publicly warned about many of these risks.

Instead, their ads highlighted weight loss while failing to mention potentially life-threatening complications. Despite extensive evidence — animal studies, clinical trials, adverse event databases, and even international regulatory alerts — Novo Nordisk continued to promote Ozempic as safe and effective, downplaying or omitting the full risk profile.

The bottom line? Patients weren’t given the facts. And as prescriptions skyrocket, so does the need for transparency, accountability, and legal consequences for Big Pharma companies that put profits ahead of people.

Want to find out if you or a loved one has an Ozempic claim?

Please feel free to contact an Ozempic Lawsuit attorney at info@westrikeback.com or 1-877-542-4646. One of our experienced Ozempic Lawsuit lawyers will help evaluate your claim and explain your legal rights for free. McSweeney / Langevin is providing consultations to individuals throughout the United States. Information provided by email or phone will be kept confidential.